Immunome, Inc. filings document the company’s targeted oncology business, public-company governance, capital structure, and material event disclosures. Its 8-K reports cover operating results, business updates, clinical and regulatory communications for programs such as varegacestat and IM-1021, investor presentations, and equity financing activity involving its common stock.
Proxy materials describe board matters, stockholder voting items, executive compensation, equity plans, and governance practices. The filing record also reflects Nasdaq-listed common stock, stock-based compensation arrangements, and formal disclosures tied to the development of antibody-drug conjugates, gamma secretase inhibition, and FAP-targeted radiotherapy within Immunome’s oncology pipeline.
Immunome Inc. filing an Amendment (Schedule 13G/A) reports that Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen each report beneficial ownership of 0% of Immunome common stock as of the close of business on March 31, 2026. The amendment states the reporting persons have no sole or shared voting or dispositive power over any shares reported on that date.
Immunome, Inc. Schedule 13G/A reports that Redmile Group, LLC and Jeremy C. Green each beneficially hold 5,558,885 shares of common stock, representing 4.9% of the class based on 113,133,199 shares outstanding as of February 27, 2026. The filing states these shares are owned by Redmile-managed investment vehicles and that both Redmile and Mr. Green disclaim direct beneficial ownership except for any pecuniary interest. The ownership figures are presented as of March 31, 2026 and the schedule is signed on May 15, 2026.
T. Rowe Price Investment Management, Inc. reported beneficial ownership of 16,364,011 shares of Immunome Inc. common stock, representing 14.5% of the class. The filing (Amendment No. 1) lists voting and dispositive powers and identifies T. Rowe Price Small-Cap Stock Fund as holding 5,764,704 shares (5.2%). Signature dated 05/15/2026 appears on the amendment; a date of 03/31/2026 is shown near the cover. The filing states the adviser acts on behalf of clients and disclaims beneficial ownership on its own behalf.
Immunome Inc. reporting persons Sirenia Capital Management and Alex Silverstein reported beneficial ownership of 6,895,000 shares of common stock, representing 6.1% of the class based on 113,133,199 shares outstanding as of February 27, 2026. The holdings are shown as shared voting and dispositive power. The filing is a Schedule 13G joint statement filed under Rule 13d-1(k).
Immunome, Inc. reported a larger net loss as it accelerated investment in its oncology pipeline but ended the quarter with substantial cash. For the three months ended March 31, 2026, net loss was $53.8 million versus $41.6 million a year earlier, driven mainly by higher research and development spending of $46.4 million and general and administrative expenses of $13.0 million. There was no collaboration revenue, compared with $2.9 million in the prior-year period, after the AbbVie agreement ended in 2025.
Cash and cash equivalents were $582.7 million as of March 31, 2026, supported by 2025 equity raises and an at-the-market program, which management expects will fund operations for at least 12 months from the report filing date. The company advanced several key programs: it submitted a new drug application for desmoid tumor candidate varegacestat, received IND clearance for ADC IM-1617, initiated a Phase 1 trial for radioligand therapy IM-3050, and continues Phase 1 development of ADC IM-1021 and IND-enabling work on preclinical ADCs IM-1340 and IM-1335.
Immunome, Inc. reported first quarter 2026 results and highlighted major advances in its oncology pipeline. For the quarter ended March 31, 2026, the company recorded a net loss of $53.8 million, or $0.48 per share, compared with a net loss of $41.6 million a year earlier, as research and development expenses rose to $46.4 million. Cash and cash equivalents were $582.7 million, which the company believes can fund operations into 2028.
Strategically, Immunome submitted a New Drug Application to the U.S. FDA in April 2026 for varegacestat in adults with desmoid tumors, following the Phase 3 RINGSIDE trial. That trial showed an 84% reduction in the risk of disease progression or death versus placebo, with a hazard ratio of 0.16 and objective response rate of 56% vs. 9%. The company also advanced multiple antibody-drug conjugate programs, with IM-1021 in Phase 1, IM-3050 initiating Phase 1, and IM-1617 receiving IND clearance.
Immunome, Inc. is asking stockholders to vote at its virtual 2026 Annual Meeting on June 9, 2026 at 12:00 p.m. Eastern Time. Key items are electing three Class III directors (James Boylan, Sandra Swain, M.D. and Philip Wagenheim), ratifying Ernst & Young LLP as auditor, an advisory vote on executive pay and an advisory vote on how often to hold future say-on-pay votes, with the Board recommending one year.
The company highlights 2025 as a pivotal year, including positive Phase 3 RINGSIDE data for varegacestat in progressing desmoid tumors, positioning for a planned NDA filing in the second quarter of 2026, and progress across its ADC and radioligand pipeline, including IM-1021, IM-1617, IM-1340, IM-1335 and IM-3050. Management notes Immunome’s share price approximately doubled between January and December 2025 and emphasizes a pay-for-performance compensation program where 2025 annual cash incentives paid above target and long-term incentives are primarily stock options that vest over four years.
Immunome Inc. Chief Scientific Officer Jack Higgins sold 9,438 shares of common stock at $21.64 per share on April 2, 2026 in an open-market transaction. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 19, 2025, indicating it was scheduled in advance. Following the sale, Higgins directly holds 22,000 shares of Immunome common stock. He is also listed as custodian for three separate 1,000-share accounts for his children under the Uniform Transfer to Minors Act, but he disclaims beneficial ownership of those custodial shares, which are subject to a lockup agreement dated December 15, 2025.
Immunome Inc. Chief Financial Officer Max Rosett exercised stock options to acquire 71,561 shares of common stock on April 2, 2026, at exercise prices of $1.05 and $1.35 per share. These options were fully vested and had original expiration dates in 2032 and 2033.
On the same day, Rosett sold a total of 65,000 Immunome shares in open-market transactions at weighted average prices of $21.91 and $22.48 per share under a pre-arranged Rule 10b5-1 trading plan. After these transactions, he directly owned 54,037 shares of Immunome common stock.